Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent P2-VP8 subunit rotavirus vaccine
- Development stage
- Phase 3
- Lead developer
- PATH
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent P2-VP8 subunit rotavirus vaccine is an investigational **intramuscular, non-replicating recombinant protein-subunit vaccine** intended to prevent severe rotavirus gastroenteritis in infants. It contains recombinant VP8 subunits derived from human rotavirus strains DS-1 P[4], 1076 P[6], and Wa P[8], each fused to the tetanus-toxoid P2 helper-T-cell epitope and adsorbed to aluminum hydroxide. PATH led development with SK bioscience as a commercial-development partner. Although the candidate was safe and immunogenic in clinical studies, its pivotal Phase 3 trial was stopped early after interim and final analyses found inferior protection against severe rotavirus gastroenteritis relative to oral Rotarix. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7482676/))
- Other names
- TV P2-VP8trivalent P2-VP8trivalent rotavirus P2-VP8 subunit vaccineP2-VP8-P[4/6/8]
02
Targets
VP4 (Rotavirus VP4)
Beyond the preview
Go deeper on trivalent P2-VP8 subunit rotavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent P2-VP8 subunit rotavirus vaccine.